Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
Cidara Therapeutics (Nasdaq: CDTX) will present a late-breaking abstract at the 10th ESWI Influenza Conference in Valencia, Spain, Oct 20-23, 2025.
The presentation, titled "Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study," will be delivered by Voon Ong, Ph.D. in the Late Breakers: Novel and Outstanding Discoveries session on Thursday, October 23, 2025, 2:00-3:30 pm CET.
Cidara Therapeutics (Nasdaq: CDTX) presenterà un abstract di ultima ora al 10° ESWI Influenza Conference a Valencia, in Spagna, dal 20 al 23 ottobre 2025.
La presentazione, intitolata "Efficacia traslazionale di CD388, un nuovo Coniugato Fc-Drug (DFC), in modelli di infezione da influenza nei topi: applicazione all''efficacia preventiva nello studio clinico Ph2b NAVIGATE recentemente completato," sarà tenuta da Voon Ong, Ph.D. nella sessione Late Breakers: Nuove Scoperte e Innovazioni il giovedì 23 ottobre 2025, 14:00-15:30 CET.
Cidara Therapeutics (Nasdaq: CDTX) presentará un resumen de última hora en la 10ª Conferencia ESWI Influenza en Valencia, España, del 20 al 23 de octubre de 2025.
La presentación, titulada "Eficacia traslacional de CD388, un nuevo Conjugado Fc-Drug (DFC), en modelos de infección por gripe en ratones: aplicación a la eficacia de la prevención en el recientemente completado estudio clínico Ph2b NAVIGATE," será presentada por Voon Ong, Ph.D. en la sesión Late Breakers: Nuevas y Destacadas Descubrimientos el jueves 23 de octubre de 2025, 14:00-15:30 CET.
Cidara Therapeutics (나스닥: CDTX)가 2025년 10월 20-23일 스페인 발렌시아에서 열리는 제10회 ESWI 독감 컨퍼런스에서 최종 발표 초록을 발표합니다.
발표 제목은 "CD388의 번역효과, 새로운 약물 Fc-접합체(DFC)의 마우스 독감 감염 모델에서의 번역적 효능: 최근 완료된 Ph2b NAVIGATE 임상 연구에서의 예방 효능에의 적용,"이며 Voon Ong, Ph.D.가 2025년 10월 23일 목요일 CET 14:00-15:30에 열리는 Late Breakers: Novel and Outstanding Discoveries 세션에서 발표합니다.
Cidara Therapeutics (Nasdaq: CDTX) présentera un résumé de dernière heure lors de la 10e Conférence ESWI Influenza à Valence, en Espagne, du 20 au 23 octobre 2025.
La présentation, intitulée "Efficacité translationnelle de CD388, un nouveau Conjugué Fc-Drug (DFC), dans des modèles d'infection grippale chez la souris : application à l'efficacité de prévention dans l'étude clinique Ph2b NAVIGATE récemment achevée," sera présentée par Voon Ong, Ph.D. dans la session Late Breakers: Novel and Outstanding Discoveries le jeudi 23 octobre 2025, 14:00-15:30 CET.
Cidara Therapeutics (Nasdaq: CDTX) wird auf der 10. ESWI Influenza-Konferenz in Valencia, Spanien, vom 20. bis 23. Oktober 2025 ein aktualisiertes Abstract vorstellen.
Die Präsentation mit dem Titel "Übersetzungsbezogene Wirksamkeit von CD388, einem neuartigen Drug Fc-Conjugate (DFC), in Maus-Influenza-Infektionsmodellen: Anwendung auf die Präventionswirksamkeit in der kürzlich abgeschlossenen Ph2b NAVIGATE-Studie," wird von Voon Ong, Ph.D. in der Session Late Breakers: Novel and Outstanding Discoveries am Donnerstag, 23. Oktober 2025, 14:00-15:30 CET vorgestellt.
Cidara Therapeutics (ناسداك: CDTX) ستقدم ملخصاً عاجلاً في المؤتمر العاشر للإنفلونزا ESWI في فالنسيا، إسبانيا، من 20 إلى 23 أكتوبر 2025.
سيُقدَّم العرض التقديمي بعنوان "فعالية الترجمة لـ CD388، مركب Fc-دواء (DFC) الجديد، في نماذج عدوى الإنفلونزا عند الفئران: تطبيق على فاعلية الوقاية في دراسة NAVIGATE السريرية Ph2b المكتملة مؤخرًا،" من قِبل فون أنتغ، دكتوراه في جلسة Late Breakers: Nuve l and Outstanding Discoveries يوم الخميس 23 أكتوبر 2025، الساعة 14:00-15:30 بتوقيت وسط أوروبا.
Cidara Therapeutics (纳斯达克: CDTX) 将在西班牙瓦伦西亚举办的第10届 ESWI 流感会议上提交一份晚期前瞻摘要，时间为 2025 年 10 月 20-23 日。
此次演讲题为 "CD388 的转化性效应，一种新型药物 Fc-结合物（DFC）在小鼠流感感染模型中的应用：对最近完成的 Ph2b NAVIGATE 临床研究的预防效应的应用，" 由 Voon Ong, Ph.D. 于 2025 年 10 月 23 日，星期四，欧洲中部时间 14:00-15:30 的 Late Breakers: Novel and Outstanding Discoveries 会场进行报告。
- None.
- None.
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.
Presentation details are summarized below:
Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study.
Presenter: Voon Ong, Ph.D.
Session: Late Breakers: Novel and Outstanding Discoveries
Session Date and Time: Thursday, October 23, 2025, 2:00-3:30 pm CET
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) present at the ESWI 10th Influenza Conference?
What is the title of Cidara's late-breaking abstract at ESWI 2025?
Who is presenting Cidara's abstract on CD388 at ESWI 2025?
Which session will Cidara's presentation appear in at the ESWI conference?
What topic does Cidara's ESWI presentation on CD388 cover?
Where and when is the ESWI 10th Influenza Conference taking place?
